Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Treating mTNBC: A Safety Analysis of Sacituzumab Govitecan

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    According to a safety analysis of the phase 3 ASCENT trial focusing on sacituzumab govitecan for patients with metastatic triple-negative breast cancer (mTNBC), neutropenia and diarrhea are the two most common adverse events associated with this treatment option, which can directly impact our management approach. Learn more about the findings and implications of this safety analysis with Dr. Charles Turck and study author Dr. Hope Rugo.

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    According to a safety analysis of the phase 3 ASCENT trial focusing on sacituzumab govitecan for patients with metastatic triple-negative breast cancer (mTNBC), neutropenia and diarrhea are the two most common adverse events associated with this treatment option, which can directly impact our management approach. Learn more about the findings and implications of this safety analysis with Dr. Charles Turck and study author Dr. Hope Rugo.

Schedule24 Nov 2024